Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cc-401. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 known ✓ | P45983 | 1/20 | 0.98 |
| ▸ | MAPK9 known ✓ | P45984 | 1/20 | 0.98 |
| ▸ | MAPK10 known ✓ | P53779 | 1/20 | 0.98 |
| ▸ | CLK2 | P49760 | 3/20 | 0.98 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.98 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.98 |
| ▸ | GAK | O14976 | 1/20 | 0.98 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.98 |
| ▸ | JAK2 | O60674 | 1/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.98 |
| ▸ | NQO2 | P16083 | 1/20 | 0.98 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.98 |
| ▸ | FECH | P22830 | 1/20 | 0.98 |
| ▸ | JAK1 | P23458 | 1/20 | 0.98 |
| ▸ | TYK2 | P29597 | 1/20 | 0.98 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.98 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.98 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.98 |
| ▸ | CLK1 | P49759 | 1/20 | 0.98 |
| ▸ | GSK3B | P49841 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cc-401 SCHEMBL29538788 | 1.00 | CLK2 (0.98) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| Cc-401 SCHEMBL29249167 | 1.00 | CLK2 (0.98) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| Cc-401 SCHEMBL29403560 | 1.00 | CLK2 (0.98) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| Cc-401 SCHEMBL30198024 | 1.00 | CLK2 (0.98) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| Cc-401 SCHEMBL30290855 | 0.99 | CLK2 (1.00) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| SCHEMBL8253744 | 0.99 | CLK2 (1.00) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| Cc-401 SCHEMBL4604749 | 0.99 | CLK2 (1.00) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| SCHEMBL5373334 | 0.98 | CLK2 (0.98) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| SCHEMBL5375716 | 0.94 | CLK2 (0.91) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| SCHEMBL5372579 | 0.91 | CLK2 (0.84) | CLK2DYRK1AMAP4K4GAKDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | claimed |
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | LINK THERAPEUTICS, LLC | 2025-10-07 | — | — | US | disclosed |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | disclosed |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | INSR, IRS1, INSRR | MAPK8 1803/4885MAPK9 2549/4885MAPK10 2203/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | MAPK8 1958/4885MAPK9 2843/4885MAPK10 2119/4885 |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | INSR, IRS1, INSRR | MAPK8 1803/4885MAPK9 2549/4885MAPK10 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.